Top Global M&A Deals 2023: Health Care Industry

SHARE:

Welcome to the Institute for Mergers, Acquisitions, and Alliances’ overview of the Top Global M&A Deals 2023: Health Care Industry. This is your essential guide to the deals that are shaping this vital sector. From long-established manufacturers of medical devices to emerging companies specializing in telehealth solutions, our monthly report captures the diverse range of M&A activities that are modernizing health care.

 

The health care industry is undergoing significant transformations. Traditional manufacturers are increasingly integrating smart technologies into medical devices, while new players are leveraging data analytics and machine learning to revolutionize patient care. Mergers and acquisitions serve as critical enablers of these innovative shifts, providing the means for companies to expand their capabilities and reach. 

 

The health care industry is a vast and multifaceted field that encompasses an extensive array of products and services. These range from surgical instruments, diagnostic machines, and medical imaging devices to wearable health monitors, telemedicine platforms, and even hospital beds and furniture. The industry is also feeling the impact of broader societal changes, such as the aging population and the growing focus on preventative healthcare, which are driving demand for innovative, cost-effective solutions. These factors are leading to an increase in healthcare M&A activities aimed at consolidating resources and accelerating innovation.   

 

As you explore our 2023 report on health care M&A, you’ll discover a monthly breakdown of the top deals, offering insights into how the industry is adapting to advances in medical technology, patient expectations, and industry regulations.

 

Whether you’re a seasoned industry professional, an investor, or simply curious about the mechanics of the consumer world, our platform delivers a front-row seat to the ongoing evolution of the health care industry through the lens of M&A. 

July

  1. Deal 1Reata Pharmaceuticals, Inc. (United States) was acquired by Biogen Inc. (United States) for $7.3 billion USD.
  2. Deal 2CRAFT 1861 Global Holdings Inc. (Canada) was acquired by Nano Cures Inc. (United States) for $2.4 billion USD.
  3. Deal 3Versanis Bio, Inc. (United States) was acquired by Eli Lilly and Company (United States) for $1.93 billion USD.
  4. Deal 4Valentino S.p.A. (Italy) was acquired by Kering SA (France) for $1.87 billion USD.
  5. Deal 5Nextech Systems, LLC (United States) was acquired by TPG Capital, L.P. (United States) for $1.4 billion USD.

August

  1. Deal 1: Abcam plc (United Kingdom) was acquired by Danaher Corporation (United States) for $5.89 billion USD.
  2. Deal 2: Celltrion Healthcare Co., Ltd. (South Korea) was acquired by Celltrion, Inc. (South Korea) for $5.34 billion USD.
  3. Deal 3: Syntellis Performance Solutions, LLC (United States) was acquired by Strata Decision Technology, L.L.C. (United States) for $1.25 billion USD.
  4. Deal 4: Circle Health Group Limited (United Kingdom) was acquired by Pure Health LLC. (UAE) for $1.20 billion USD.
  5. Deal 5: Inversago Pharma Inc. (Canada) was acquired by Novo Nordisk A/S (Denmark) for $1.08 billion USD.

September

  1. Deal 1: NextGen Healthcare, Inc. (United States) was acquired by Thoma Bravo, L.P. (United States) for $1.88 billion USD.
  2. Deal 2: Ergomed plc (United Kingdom) was acquired by Permira Advisers Ltd. (United Kingdom) for $0.89 billion USD.
  3. Deal 3: Limacorporate S.p.A. (Italy) was acquired by Enovis Corporation (United States) for $0.87 billion USD.
  4. Deal 4: Relievant Medsystems, Inc. (United States) was acquired by Boston Scientific Corporation (United States) for $0.85 billion USD.
  5. Deal 5: Intercept Pharmaceuticals, Inc. (United States) was acquired by Alfasigma S.p.A. (Italy) for $0.79 billion USD.

October

  1. Deal 1: Mirati Therapeutics, Inc. (United States) was acquired by Bristol-Myers Squibb Company (United States) for $4.80 billion USD.
  2. Deal 2: Olink Holding AB (publ) (Sweden) was acquired by Thermo Fisher Scientific Inc. (United States) for $3.10 billion USD.
  3. Deal 3: Substantially All of the Over-the-Counter Business of Viatris Inc. (United States) was acquired by Cooper Consumer Health SAS (France) for $2.17 billion USD.
  4. Deal 4: Paragon Medical, Inc. (United States) was acquired by AMETEK, Inc (United States) for $1.90 billion USD.
  5. Deal 5: POINT Biopharma Global Inc. (United States) was acquired by Eli Lilly and Company (United States) for $1.38 billion USD.

November

  1. Deal 1: ImmunoGen, Inc. (United States) was acquired by AbbVie Inc. (United States) for $10.10 billion USD.
  2. Deal 2: Taisho Pharmaceutical Holdings Co., Ltd. (Japan) was acquired by Otemon Co., Ltd. (Japan) for $4.75 billion USD.
  3. Deal 3: Coastal Carolina Hospital (United States), East Cooper Medical Center (United States), and Hilton Head Hospital (United States) was acquired by Novant Health, Inc. (United States) for $2.40 billion USD.
  4. Deal 4: Ramsay Sime Darby Health Care Sdn Bhd (Malaysia) was acquired by Columbia Asia Healthcare Pte. Ltd. (Malaysia) for $1.20 billion USD.
  5. Deal 5: Aster DM Healthcare FZC (United Arab Emirates) was acquired by Fajr Capital Advisors Limited (United Arab Emirates) for $1.00 billion USD.

December

  1. Deal 1: Karuna Therapeutics, Inc. (United States) was acquired by Bristol-Myers Squibb Company (United States) for $14.00 billion USD.
  2. Deal 2: Cerevel Therapeutics Holdings, Inc. (United States) was acquired by AbbVie Inc. (United States) for $8.70 billion USD.
  3. Deal 3: RayzeBio, Inc. (United States) was acquired by Bristol-Myers Squibb Company (United States) for $4.15 billion USD.
  4. Deal 4: Carmot Therapeutics Inc. (United States) was acquired by Roche Holding AG (Switzerland) for $3.10 billion USD.
  5. Deal 5: Icosavax, Inc. (United States) was acquired by AstraZeneca PLC (United Kingdom) for $1.10 billion USD.

TAGS:

Stay up to date with M&A news!

Subscribe to our newsletter

    Are you sure you
    want to log out?

    In order to become a charterholder you need to complete one of the IMAA programs